Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?

Could now be the right time to add both Indivior PLC (LON: INDV) and AstraZeneca plc (LON: AZN) to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Shares in Reckitt Benckiser spin-off, Indivior (LSE: INDV), were as much as 18% weaker today after the pharmaceutical company released a disappointing set of full-year results. The FTSE 250-listed firm, which has a market capitalisation of £2.3bn, reported a lower pre-tax profit than expected as a result of generic competition in the US and price pressure in the EU, which was at least partly caused by continued government austerity in the region.

In addition, the company’s outlook for 2015 is somewhat challenging, as it has stated in today’s update that it is ‘very uncertain as to the timing, extent and impact of tablet price erosion’. As such, its guidance of net income of $130m to $155m for the current year could be subject to significant change as we move through the year, which is clearly a major negative for investors in the company.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

And, even though the company’s key drug, Suboxone Film, has proved somewhat resilient in 2014 and still commands a market share of 58% in the US (down from 67% in 2013), it could see further falls in revenue as cheaper, generic alternatives cause even the most loyal of customers to switch to more economically viable products.

Looking Ahead

Clearly, the present time is highly uncertain for Indivior and the company’s share price is likely to come under further pressure in the short term, until more is known regarding the trading landscape both in the US and in Europe. However, much of this appears to be priced in to the company’s current share price, with it offering a very wide margin of safety at the present time.

For example, assuming a pretax profit of around $143m in 2015 (the midpoint of the company’s guided range of $130m to $155m) means that Indivior trades on a price to earnings (P/E) ratio of 16.4 which, for a major pharmaceutical company, appears to equate to relatively good value for money.

In fact, sector peer, AstraZeneca (LSE: AZN) (NYSE: AZN.US) also trades on a P/E ratio of 16.4 despite still experiencing the effects of a patent cliff, where its top and bottom lines are continuing to experience severe pressure from generic alternatives. As such, AstraZeneca is not expected to begin growing its bottom line until 2017 at the earliest and, as a result, the medium term outlook for the company remains highly uncertain, which is a similar position to that which Indivior currently faces.

Therefore, while today’s results are disappointing and Indivior’s prospects are highly uncertain, now could be a good time to buy a slice of it. Not only does it seem to offer a considerable margin of safety for a major pharmaceutical stock, it also trades on the same rating as AstraZeneca. Certainly, the next couple of years will be somewhat volatile for investors in both companies but, in the long run, they could deliver superb gains and, as such, seem to make a sound combination play.

More on Investing Articles

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

UK shares: 1 cheap dividend stock I bought to combat inflation!

This Fool is on the lookout for the best UK shares to protect himself from soaring inflation. Here is one…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

A beaten-down penny stock to buy on the dip!

This penny stock is down 12% in just a few weeks. But at the current price, it looks like a…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

Should I buy Marks and Spencer shares for its growth in July?

Despite posting excellent annual results, Marks and Spencer shares are down 40% this year. Could this be a buying opportunity…

Read more »

Stack of one pound coins falling over
Investing Articles

The Lloyds dividend could keep growing – but will it?

Our writer explains why he's not taking the prospect of a growing Lloyds dividend for granted.

Read more »

Shot of an young Indian businesswoman sitting alone in the office at night and using a digital tablet
Investing Articles

Are BT shares a good buy at 185p?

BT shares offer a fairly attractive dividend and are down considerably over four years. But is this stock right for…

Read more »

An airplane on a runway
Investing Articles

The Rolls-Royce share price is down one-third. Should I buy?

The Rolls-Royce share price has lost a third of its value since the year began. Our writer explains why he…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

Down 57%, cheap NIO shares are ‘no-brainer’ additions to my portfolio!

NIO shares have risen considerably in recent months, but are down over the year. I'm still buying this stock for…

Read more »

Young woman with face mask using mobile phone and buying groceries in the supermarket during virus pandemic.
Investing Articles

Will a recession help or hurt the B&M share price?

The B&M share price has been tumbling and there's a recession looming, So why would our writer still consider adding…

Read more »